Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CDK2 | P24941 | 16/20 | 0.53 |
| ▸ | CDK1 | P06493 | 13/20 | 0.53 |
| ▸ | KDR | P35968 | 12/20 | 0.53 |
| ▸ | WEE1 | P30291 | 1/20 | 0.39 |
| ▸ | CDK9 | P50750 | 4/20 | 0.36 |
| ▸ | PTK2 | Q05397 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13021780 | 1.00 | CDK2 (0.53) | CDK2CDK1KDRWEE1CDK9 | |
| SCHEMBL13021783 | 0.95 | CDK2 (0.55) | CDK2CDK1KDRWEE1CDK9 | |
| SCHEMBL2819486 | 0.95 | CDK2 (0.55) | CDK2CDK1KDRWEE1CDK9 | |
| SCHEMBL13021766 | 0.93 | CDK2 (0.55) | CDK2CDK1KDRWEE1CDK9 | |
| SCHEMBL2821902 | 0.93 | CDK2 (0.55) | CDK2CDK1KDRWEE1CDK9 | |
| SCHEMBL2817915 | 0.91 | CDK2 (0.56) | CDK2CDK1KDRWEE1CDK9 | |
| SCHEMBL13021791 | 0.91 | CDK2 (0.56) | CDK2CDK1KDRWEE1CDK9 | |
| SCHEMBL13021802 | 0.91 | CDK2 (0.53) | CDK2CDK1KDRWEE1CDK9 | |
| SCHEMBL13021813 | 0.91 | CDK2 (0.53) | CDK2CDK1KDRWEE1CDK9 | |
| SCHEMBL13021822 | 0.90 | CDK2 (0.53) | CDK2CDK1KDRWEE1CDK9 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7825128-B2 | Sulfoximine-substituted pyrimidines, processes for production thereof and use thereof as drugs | BAYER SCHERING PHARMA AG (DE) | 2010-11-02 | — | — | US | disclosed |
| EP-1963282-A1 | SULFOXIMINE-SUBSTITUTED PYRIMIDINES , THEIR PREPARATION AND USE AS DRUGS | Bayer Schering Pharma Aktiengesellschaft (DE) | 2008-09-03 | — | — | EP | disclosed |
| US-20070232632-A1 | Sulfoximine-substituted pyrimidines, processes for production thereof and use thereof as drugs | BAYER INTELLECTUAL PROPERTY GMBH (DE) | 2007-10-04 | — | — | US | disclosed |
| WO-2007071455-A1 | SULFOXIMINE-SUBSTITUTED PYRIMIDINES , THEIR PREPARATION AND USE AS DRUGS | BAYER SCHERING PHARMA AKTIENGESELLSCHAFT (DE) | 2007-06-28 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070232632-A1 | Sulfoximine-substituted pyrimidines, processes for production thereof and use thereof as drugs | TYMS, DPYD, DHFR | CDK2 664/4885CDK1 876/4885KDR 1262/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.